Do you want to live forever? Many billionaires want to, or at least want to support the research into improving and extending the lives of people. Paul Allen, co-founder of Microsoft (MSFT) created the Allen Institute for Cell Science with $100 million, to develop treatments for diseases related to aging. Unfortunately, he passed away last year from septic shock caused by cancer.
Adam Neumann, the CEO of WeWork, has invested in the anti-aging company Life Biosciences. Peter Thiel, co-founder of PayPal (PYPL), has donated money to the SENS Research Foundation, a longevity organization. Google (GOOG) (GOOGL) co-founder Sergey Brin has donated to the Michael J. Fox Foundation and to the Parkinson’s Institute.
There are many companies involved in longevity through several different approaches, including medical devices, biotechnology, pharmaceuticals, and senior care facilities.
One company that fits into this category is Edwards Lifesciences (EW), a California based company involved in the production of products to treat heart disease. This $44.7 billion market cap company trades at 44 times trailing earnings and 35 times forward earnings. Earnings for the latest reported year were up 23.7% over the previous year.
Boston Scientific (BSX), a $60 billion market cap company, makes and markets an extensive array of cardiology products. The sock has a trailing price-to-earnings ratio of 43 and a forward PE ratio of 24.
Vertex Pharmaceuticals Incorporated (VRTX) developer and markets treatments for cystic fibrosis. The stock trades at 21 times earnings.
Terumo Corporation (TRUMY), based in Japan, makes and markets numerous medical products, primarily for transfusion and cardiothoracic surgery. The stock has a PE ratio of 13.
All of the above, plus many other longevity related stocks make up the portfolio of the Global X Longevity Thematic ETF (LNGR), which has a portfolio of anti-aging stocks. It pays a small yield of 0.85%.
Hopefully some of these stocks will make your portfolio last a long time.
Disclosure: Author didn’t own any of the above at the time the article was written.